AxonixxAxonixx

02 · Product

Run the trial
before the trial.

Statistically realistic synthetic populations — so drug candidates get stress-tested in-silico long before the first human dose.

Vast lattice of translucent virtual human silhouettes receding into darkness

Overview

A pipeline that begins in simulation.

Nine out of ten candidates that enter human trials never reach the market — most fail on physiological variation only discovered at Phase II or III.

Run candidates against millions of synthetic patients calibrated to real distributions. Efficacy, safety, and stratification signals surface in weeks, not years.

Interactive

Find the safe-effective dose. Without dosing anyone.

IN-SILICO DOSE–RESPONSE · N = 10,000 · COHORT: GENERAL
THERAPEUTIC WINDOW · EFF ≥ 50% · AE ≤ 15%
100%75%50%25%0%0mg25mg50mg75mg100mgTHERAPEUTIC WINDOW · 41–67 mg45 mgefficacyadverse eventstherapeutic window

Responders

61%

6,100 / 10,000

Adverse events

1%

100 / 10,000

Net benefit

+60

in window

Cohort

Drag chart or arrow keys to change dose.

Method

From biology to synthetic cohort.

  1. Step 01

    Calibrate

    Generator calibrated on de-identified clinical and biobank data.

  2. Step 02

    Instantiate

    Millions of virtual patients as full physiological simulations.

  3. Step 03

    Dose

    PK/PD models couple drug candidates to each patient's physiology.

  4. Step 04

    Report

    Efficacy, adverse events, and responder subgroups with confidence intervals.

Applications

Every stage, compressed.

Target validation

Test mechanism-of-action hypotheses before wet-lab commitment.

Trial design

Optimize sample size, arms, and stratification in-silico first.

Rare disease

Defensible cohorts where real patients are too few to power a trial.

Combination therapy

Explore combinatorial dose spaces impossible to run in humans.

Science

Grounded in physiology, honest about uncertainty.

  • METHOD

    Population-scale physiological simulation with calibrated variance

    Internal, 2025
  • PAPER

    Synthetic cohorts as complements to real-world evidence

    Preprint, 2025
  • PARTNER

    In-silico trial pilots with pharma and CRO partners

    In collaboration
  • STANDARD

    FDA Model-Informed Drug Development (MIDD)

    Guidance track

FAQ

What sponsors ask before a first pilot.

Can virtual trials replace human trials?

No — they complement human studies, so sponsors enter with a sharper hypothesis and better protocols.

How is the population validated?

Benchmarked against held-out real-world cohorts, with explicit uncertainty and OOD warnings.

What therapeutic areas?

General platform, with initial depth in cardiovascular, metabolic, oncology, and neurology.

How do we start?

A small number of pharma partners onboard each quarter into structured pilots. Reach out via /contact.

Continue exploring

01

World Models for Diagnosis

Simulate patient physiology to catch disease early.

03

Non-invasive Migraine Therapy

Wearable neural stimulation. Drug-free relief.

Partnerships

Building in adjacent healthcare, pharma, or neurotech? Let's talk.

Contact Axonixx